Imbruvica first gained FDA approval in 2013 to treat patients with mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström’s macroglobulinemia, small lymphocytic lymphoma, and marginal zone lymphoma. Now, the drug can also be used to treat patients with marginal zone lymphoma who require systemic therapy and have received at least one type of lymphoma therapy.
The continued approval of this indication may be contingent upon the positive clinical outcomes from a confirmatory clinical trial, according to a news release.
Janssen Biotech, a subsidiary of Johnson & Johnson, and Pharmacyclics, an AbbVie company, partnered to develop and commercialize the drug.
More articles on supply chain:
Amid heavy criticism of drug prices, pharma group launches ad campaign to improve image
What would happen if we ditched annual price hikes? 4 responses from pharma execs
ACA repeal and replace will include action on drug prices, Spicer says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
